Chairman and Chief Executive Officer Randal J. Kirk said the new market alignment will help Intrexon achieve its vision to be one of the leading life science companies in the world.
"Our new sector organization, led by an outstanding team of industry veterans, will bring additional focus and rapidity to solving our partners' toughest synthetic biology problems," Kirk said. "It's a very exciting step toward empowering the bioindustrial revolution with solutions that enhance the quality and diversity of life."
About Intrexon CorporationIntrexon Corporation is a privately held biotechnology company focused on collaborating with companies in Health, Food, Energy and the Environment to create bio-based products that improve the quality of life and the health of the planet. Through the company's proprietary UltraVector® platform, Intrexon provides its partners with industrial-scale design and development of multigenic biology. UltraVector delivers unprecedented control over the quality, reliability, and performance of living cells. We call it Better DNA™ and we invite you to discover more at www.dna.com.
TrademarksIntrexon, UltraVector, mAbLogix and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Safe Harbor StatementSome of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these f
|SOURCE Intrexon Corporation|
Copyright©2012 PR Newswire.
All rights reserved